Compare Heron Therapeutics Inc (HRTX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while T Rowe Price Group Inc trades at $104.25 (market cap $22.20B). The key difference: T Rowe Price Group Inc is far larger — about 299.8× Heron Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 5% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and T Rowe Price Group Inc for 115 Days on average.
| HRTX | TROW | |
|---|---|---|
Market Cap | $74.04M | $22.20B |
Volume | 3,668,095 | 1,738,431 |
Sector | Health | Financials |
52-Week High | $1.49 | $121.68 |
52-Week Low | $0.27 | $86.19 |
Typical Hold Time | 35 Days | 115 Days |
Enterprise Value | $180.78M | $19.39B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
T. Rowe Price (TROW) trades at $104.23, up 0.61% with bearish technical signals but strong fundamentals including a 29.26% net margin and $2.09B net income. The stock shows consistent earnings beats and dividend growth, supported by $1.90 trillion in assets under management as of August 2026. Recent news highlights dividend sustainability and ETF expansion through acquisitions.
Outlook remains positive with a $112 consensus price target offering 7.5% upside, though technical weakness and market volatility pose near-term risks. The company's 40-year dividend growth history and expanding product portfolio provide stability, while net outflows and competitive pressures require monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
